Alembic Pharmaceuticals Limited announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol Myers Squibb Company (BMS).
- Read more about Alembic Pharmaceuticals receives USFDA Tentative approval for Dasatinib Tablets
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/alembic-pharmaceuticals-receives-usfda-tentative-approval-for-dasatinib-tablets
No comments:
Post a Comment